INOVIQ Confirms positive EXO-NET results in ovarian cancer study
- INOVIQ (IIQ) confirms positive results during its testing for ovarian cancer
- The company wrapped up its Ovarian Cancer 97 study, which was undertaken by the Centre for Clinical Research at The University of Queensland
- The study confirmed the utility of EXO-NET for extracellular vesicle (EV) biomarker discovery, with over 90 per cent accuracy for the detection of early-stage ovarian cancer
- The company says its next steps will include an analytical validation study to establish equivalence of the EV-based ovarian cancer test in plasma compared to serum from the same cohort of patients
- The company climbs 13.9 per cent, trading at 69.5 cents at 3:06 pm AEDT
